Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.
The structure of VRC01 in complex with the HIV-1 gp120 core reveals that this broadly neutralizing CD4 binding site (CD4bs) antibody partially mimics the interaction of the primary virus receptor, CD4, with gp120. Here, we extended the investigation of the VRC01-gp120 core interaction to the biologically relevant viral spike to better understand the mechanism of VRC01-mediated neutralization and to define viral elements associated with neutralization resistance. In contrast to the interaction of CD4 or the CD4bs monoclonal antibody (MAb) b12 with the HIV-1 envelope glycoprotein (Env), occlusion of the VRC01 epitope by quaternary constraints was not a major factor limiting neutralization. Mutagenesis studies indicated that VRC01 contacts within the gp120 loop D, the CD4 binding loop, and the V5 region were necessary for optimal VRC01 neutralization, as suggested by the crystal structure. In contrast to interactions with the soluble gp120 monomer, VRC01 interaction with the native viral spike did not occur in a CD4-like manner; VRC01 did not induce gp120 shedding from the Env spike or enhance gp41 membrane proximal external region (MPER)-directed antibody binding to the Env spike. Finally, VRC01 did not display significant reactivity with human antigens, boding well for potential in vivo applications. The data indicate that VRC01 interacts with gp120 in the context of the functional spike in a manner distinct from that of CD4. It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike.
VRC01 与 HIV-1 gp120 核心复合物的结构表明,这种广泛中和的 CD4 结合位点(CD4bs)抗体部分模拟了主要病毒受体 CD4 与 gp120 的相互作用。在这里,我们将 VRC01-gp120 核心相互作用扩展到具有生物学相关性的病毒刺突,以更好地理解 VRC01 介导的中和机制,并确定与中和耐药性相关的病毒元件。与 CD4 或 CD4bs 单克隆抗体(MAb)b12 与 HIV-1 包膜糖蛋白(Env)的相互作用相反,四级限制对 VRC01 表位的封闭不是限制中和的主要因素。突变研究表明,VRC01 在 gp120 环 D、CD4 结合环和 V5 区域内的接触对于 VRC01 的最佳中和是必要的,这与晶体结构一致。与可溶性 gp120 单体的相互作用相反,VRC01 与天然病毒刺突的相互作用不以 CD4 样方式发生;VRC01 不会诱导 gp120 从 Env 刺突上脱落,也不会增强 gp41 膜近端外部区域(MPER)导向抗体与 Env 刺突的结合。最后,VRC01 与人类抗原没有明显的反应性,这对于潜在的体内应用是个好兆头。数据表明,VRC01 以不同于 CD4 的方式与功能刺突中的 gp120 相互作用。它通过精确靶向 CD4bs 实现有效的中和,而不需要改变 Env 刺突的构象,并避免由功能性 Env 刺突的四级结构引起的空间位阻。